Logo image of CTX.CA

CRESCITA THERAPEUTICS INC (CTX.CA) Stock Fundamental Analysis

TSX:CTX - Toronto Stock Exchange - CA2258471028 - Common Stock - Currency: CAD

0.55  -0.04 (-6.78%)

Fundamental Rating

3

Taking everything into account, CTX scores 3 out of 10 in our fundamental rating. CTX was compared to 35 industry peers in the Pharmaceuticals industry. CTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

CTX had negative earnings in the past year.
CTX had a positive operating cash flow in the past year.
In multiple years CTX reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: CTX reported negative operating cash flow in multiple years.
CTX.CA Yearly Net Income VS EBIT VS OCF VS FCFCTX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M -10M -15M

1.2 Ratios

The Return On Assets of CTX (-12.07%) is comparable to the rest of the industry.
CTX has a Return On Equity of -17.05%. This is comparable to the rest of the industry: CTX outperforms 56.76% of its industry peers.
Industry RankSector Rank
ROA -12.07%
ROE -17.05%
ROIC N/A
ROA(3y)-2.96%
ROA(5y)-0.36%
ROE(3y)-3.96%
ROE(5y)-0.58%
ROIC(3y)N/A
ROIC(5y)N/A
CTX.CA Yearly ROA, ROE, ROICCTX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K

1.3 Margins

With an excellent Gross Margin value of 55.58%, CTX belongs to the best of the industry, outperforming 83.78% of the companies in the same industry.
In the last couple of years the Gross Margin of CTX has declined.
CTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 55.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.52%
GM growth 5Y-2.37%
CTX.CA Yearly Profit, Operating, Gross MarginsCTX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K

More info and screens

6

2. Health

2.1 Basic Checks

CTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CTX has less shares outstanding
Compared to 5 years ago, CTX has less shares outstanding
Compared to 1 year ago, CTX has an improved debt to assets ratio.
CTX.CA Yearly Shares OutstandingCTX.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
CTX.CA Yearly Total Debt VS Total AssetsCTX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

CTX has an Altman-Z score of -0.98. This is a bad value and indicates that CTX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CTX (-0.98) is comparable to the rest of the industry.
CTX has a debt to FCF ratio of 6.17. This is a slightly negative value and a sign of low solvency as CTX would need 6.17 years to pay back of all of its debts.
CTX has a better Debt to FCF ratio (6.17) than 78.38% of its industry peers.
CTX has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.03, CTX is in the better half of the industry, outperforming 75.68% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF 6.17
Altman-Z -0.98
ROIC/WACCN/A
WACC8.45%
CTX.CA Yearly LT Debt VS Equity VS FCFCTX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M

2.3 Liquidity

CTX has a Current Ratio of 2.70. This indicates that CTX is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 2.70, CTX is doing good in the industry, outperforming 70.27% of the companies in the same industry.
CTX has a Quick Ratio of 1.68. This is a normal value and indicates that CTX is financially healthy and should not expect problems in meeting its short term obligations.
CTX has a better Quick ratio (1.68) than 64.86% of its industry peers.
Industry RankSector Rank
Current Ratio 2.7
Quick Ratio 1.68
CTX.CA Yearly Current Assets VS Current LiabilitesCTX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for CTX have decreased strongly by -369.67% in the last year.
CTX shows a decrease in Revenue. In the last year, the revenue decreased by -7.53%.
CTX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.05% yearly.
EPS 1Y (TTM)-369.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.33%
Revenue 1Y (TTM)-7.53%
Revenue growth 3Y3.86%
Revenue growth 5Y1.05%
Sales Q2Q%18.61%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CTX.CA Yearly Revenue VS EstimatesCTX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
CTX.CA Yearly EPS VS EstimatesCTX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTX.CA Price Earnings VS Forward Price EarningsCTX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, CTX is valued a bit cheaper than 64.86% of the companies in the same industry.
Industry RankSector Rank
P/FCF 69.85
EV/EBITDA N/A
CTX.CA Per share dataCTX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRESCITA THERAPEUTICS INC

TSX:CTX (3/6/2025, 7:00:00 PM)

0.55

-0.04 (-6.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07
Earnings (Next)03-19 2025-03-19
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners12.21%
Ins Owner ChangeN/A
Market Cap10.48M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.6
P/FCF 69.85
P/OCF 9.66
P/B 0.65
P/tB 0.74
EV/EBITDA N/A
EPS(TTM)-0.14
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.01
FCFY1.43%
OCF(TTM)0.06
OCFY10.36%
SpS0.91
BVpS0.84
TBVpS0.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.07%
ROE -17.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 55.58%
FCFM 0.86%
ROA(3y)-2.96%
ROA(5y)-0.36%
ROE(3y)-3.96%
ROE(5y)-0.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.52%
GM growth 5Y-2.37%
F-Score5
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF 6.17
Debt/EBITDA N/A
Cap/Depr 67.9%
Cap/Sales 5.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.7
Quick Ratio 1.68
Altman-Z -0.98
F-Score5
WACC8.45%
ROIC/WACCN/A
Cap/Depr(3y)16.61%
Cap/Depr(5y)13.32%
Cap/Sales(3y)1.27%
Cap/Sales(5y)1.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-369.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.33%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-7.53%
Revenue growth 3Y3.86%
Revenue growth 5Y1.05%
Sales Q2Q%18.61%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-139.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-46.43%
FCF growth 3Y-29.52%
FCF growth 5YN/A
OCF growth 1Y48.63%
OCF growth 3Y-28.21%
OCF growth 5YN/A